Sun Pharmaceutical Industries reported a revenue of ?13,291 crore for the quarter, reflecting a 9% year-over-year increase and a 5% rise quarter-over-quarter. This figure surpassed our estimates by 2%, despite experiencing price reductions in Taro’s portfolio and in Japan.